{{overview_title}}
{{overview_content}}
{{mechanism_title}}
{{mechanism_content}}
{{benefits_title}}
{{research_title}}
{{research_content}}
{{safety_title}}
{{safety_content}}
Recommended products
Research peptides selected for quality and purity:
Top Pick
GHK-Cu
Anti-Aging Compound
FAQ
Is Ozempic the same as Wegovy?
Both contain the same active ingredient, semaglutide, made by the same manufacturer. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly, while Wegovy is approved for chronic weight management at a higher 2.4 mg dose. They are branded and dosed differently for their respective indications.
How much weight can you lose on semaglutide?
In the STEP clinical trials, adults taking 2.4 mg weekly alongside lifestyle changes lost an average of about 15–17% of body weight over 68 weeks, though individual results vary widely. Much of the weight tends to return if the medication is stopped, so ongoing treatment and lifestyle changes matter.
What are the most common side effects of semaglutide?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. They are usually mild to moderate and often improve over time, especially with gradual dose escalation. Rare but serious risks include pancreatitis and gallbladder disease; discuss any concerns with your doctor.
Can semaglutide be used without diabetes?
Yes. As Wegovy, semaglutide is approved for chronic weight management in adults with obesity, or with overweight plus a weight-related condition, regardless of diabetes status. The SELECT trial also showed cardiovascular benefit in people with obesity and heart disease but without diabetes.
Is semaglutide a research peptide?
No. Although semaglutide is a peptide-based molecule, it is a fully approved prescription drug, not a research-use-only compound. It should be obtained through licensed pharmacies and used under medical supervision—unregulated or compounded versions may carry quality and dosing risks.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.
- Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.
- Frias JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.
- Davies M, Færch L, Jeppesen OK, et al. (2021). Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity and Type 2 Diabetes (STEP 2). The Lancet.
- Knudsen LB, Lau J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology.